Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Baxter
Johnson and Johnson
McKinsey
Moodys

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR OXYTOCIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Oxytocin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed Basel Women’s University Hospital Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed University Hospital, Basel, Switzerland Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxytocin

Condition Name

Condition Name for Oxytocin
Intervention Trials
Postpartum Hemorrhage 81
Healthy 52
Schizophrenia 29
Oxytocin 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxytocin
Intervention Trials
Hemorrhage 153
Postpartum Hemorrhage 138
Disease 33
Schizophrenia 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxytocin

Trials by Country

Trials by Country for Oxytocin
Location Trials
United States 340
Egypt 81
Canada 63
China 42
France 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxytocin
Location Trials
California 59
North Carolina 31
New York 29
Massachusetts 27
South Carolina 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxytocin

Clinical Trial Phase

Clinical Trial Phase for Oxytocin
Clinical Trial Phase Trials
Phase 4 122
Phase 3 66
Phase 2/Phase 3 16
[disabled in preview] 142
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxytocin
Clinical Trial Phase Trials
Completed 389
Recruiting 106
Unknown status 97
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxytocin

Sponsor Name

Sponsor Name for Oxytocin
Sponsor Trials
University of Electronic Science and Technology of China 37
Samuel Lunenfeld Research Institute, Mount Sinai Hospital 29
Cairo University 21
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxytocin
Sponsor Trials
Other 966
Industry 47
NIH 38
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
Mallinckrodt
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.